CDA-AMC

Pendopharm and Ascendis Pharma Gain Canada Reimbursement Recommendation for Yorvipath

MONTREAL, Quebec, September 2, 2026 Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, announced that...

By cGxPwire Editor
September 4, 2026

Bio-Pharma

Eisai and Biogen Advance LEQEMBI Access in Canada

TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...

By cGxPwire Editor
September 1, 2026

Bio-Pharma

UCB Receives Favorable Canadian Reimbursement Opinion for BIMZELX

OAKVILLE, Ontario, June 9, 2026 UCB Canada announced that BIMZELX® (bimekizumab injection) received a positive reimbursement recommendation with conditions...

By cGxPwire Editor
June 11, 2026

.Clinical

Roche’s Gazyva Moves Closer to Public Access in Canada for Lupus Nephritis

MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...

By cGxPwire Editor
May 25, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Pendopharm and Ascendis Pharma Gain Canada Reimbursement Recommendation for Yorvipath

Eisai and Biogen Advance LEQEMBI Access in Canada

UCB Receives Favorable Canadian Reimbursement Opinion for BIMZELX

Roche’s Gazyva Moves Closer to Public Access in Canada for Lupus Nephritis